Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.17 (market cap $12.87B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.1× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 14,946,002). Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EMB | IDXX | |
|---|---|---|
Market Cap | $12.87B | $40.43B |
Volume | 14,946,002 | 692,164 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $766.68 |
52-Week Low | $90.14 | $504.70 |
Typical Hold Time | 51 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.17, showing modest daily gains of 0.43% amid a bearish technical outlook with 14 sell signals versus 6 buy signals. The stock faces resistance at $91-92 levels while maintaining dividend distributions, though key valuation metrics remain unavailable for fundamental assessment. Recent market commentary suggests limited near-term upside potential.
The outlook remains cautious with technical indicators signaling bearish momentum and Seeking Alpha maintaining a HOLD rating as of July 23, 2026. Primary investment appeal centers on income generation through dividends, though price appreciation appears constrained. Risks include broader market volatility and emerging market bond yield fluctuations affecting fixed-income alternatives.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
